Research programme: monoclonal antibodies - HiFiBiO Therapeutics
Alternative Names: HFB-2008Latest Information Update: 12 Mar 2021
At a glance
- Originator HiFiBiO
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; G protein-coupled receptor antagonists; Immunostimulants; Myeloid-derived suppressor cell inhibitors; Regulatory T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Mar 2021 Research programme: monoclonal antibodies - HiFiBiO Therapeutics is available for licensing as of 09 Mar 2021. https://hifibio.com/partnership/